Side-by-side · Research reference
HCGvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED12/52 cited
BAnimal-StrongAUTO-DRAFTED13/39 cited
HCG
Glycoprotein Hormone · LH Mimetic
IM or SQ · 2–3×/week
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
HCG
KPV
Primary target
LH receptors on testicular Leydig cellsSchröder-Lange 2025
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026Zachariou 2026
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed
No melanocortin receptor binding
Origin
Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
Rare with recombinant; possible with urinary-derived formulations
—
02Dosage Protocols
Parameter
HCG
KPV
Hypogonadotropic hypogonadism (monotherapy)
2,000 IU IM/SQ 2–3×/weekKonsam 2026Zachariou 2026
Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.
—
Combined therapy (hCG + FSH)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026Nariyoshi 2025
Preferred for azoospermia; FSH added after initial hCG phase or from outset.
—
Triple therapy (experimental)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026
May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).
—
Cryptorchidism (pediatric)
500–4,000 IU IM 2–3×/week for 3–6 weeks
—
Evidence basis
RCT / Meta-analysis / FDA-approvedKonsam 2026Huijben 2026
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Duration to sperm appearance
12–24 months (median ~18 mo)Huijben 2026Zachariou 2026
Congenital HH may require longer treatment; acquired HH responds faster.
—
Monitoring
Serum testosterone, semen analysis q3–6mo, testicular ultrasound
Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025
—
Frequency
—
Daily or 2–3× per week
Lower / starter dose
—
100 mcg / day
Duration
—
4–8 weeks per cycle
Reconstitution
—
Bacteriostatic water (SQ form)
Timing
—
No specific time; often taken with / before meals (oral)
Half-life
—
Hours (estimated; rapid tissue uptake)
04Side Effects & Safety
Parameter
HCG
KPV
Injection site reaction
Pain, erythema (mild, transient)
Mild irritation
Gynecomastia
Aromatization of elevated testosterone to estradiol; dose-dependent
—
Testicular discomfort / Edema
Rapid testicular growth in hypogonadal males; usually self-limiting
—
Polycythemia
Elevated hematocrit from supraphysiological testosterone; monitor CBC
—
Mood / Libido changes
Variable; usually positive with normalization of testosterone
—
Acne / Oily skin
Androgen-mediated; dose-dependent
—
Prostate concerns
Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)
—
Antibody formation
Rare with recombinant; possible with urinary-derived
—
GI symptoms
—
Rare nausea (oral form)
Long-term safety
—
Limited human data
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
HCG
- ·Androgen-dependent malignancy (prostate, breast cancer)
- ·Hypersensitivity to hCG or excipients
- ·Precocious puberty
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
HCG
- ·Untreated obstructive sleep apnea
- ·Severe cardiovascular disease (polycythemia risk)
- ·History of thromboembolism
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
HCG
KPV
1. Reconstitution (if lyophilized)
Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.
Add 1 mL bacteriostatic water to vial per labelling.
2. Injection site
Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).
Morning preferred; oral form taken with / before meals.
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle selection
IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).
29–31G insulin syringe (SQ form).
06Stack Synergy
HCG
— no documented stacks
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions